General infertility workup in times of high assisted reproductive technology efficacy

Fertil Steril. 2022 Jul;118(1):8-18. doi: 10.1016/j.fertnstert.2022.05.019.

Abstract

The assessments of oocyte quality and quantity and endocrine profile have traditionally been the cornerstone of the general workup of couples with infertility. Over the years, several clinical, hormonal, and functional biomarkers have been adopted to assess ovarian function and identify endocrine disorders before assisted reproductive technology. Furthermore, the genetic workup of patients has drastically changed, introducing novel markers. This not only allowed the prediction of response to ovarian stimulation but also contributed toward the development of a safer and more efficient management of women undergoing assisted reproductive technology. The scope of this review is to provide an overview of the current and novel strategies adopted for the assessment of ovarian function and ovulatory and endocrine disorders in women planning to conceive. Furthermore, it aims to provide an insight in the role of novel genetic biomarkers and use of expanded carrier screening as part of preliminary workup of women with infertility.

Keywords: Infertility workup; expanded carrier screening; oocyte quality; ovarian reserve; ovulatory disorders.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Female
  • Humans
  • Infertility* / diagnosis
  • Infertility* / therapy
  • Infertility, Female* / diagnosis
  • Infertility, Female* / therapy
  • Oocytes
  • Ovulation Induction
  • Reproductive Techniques, Assisted

Substances

  • Biomarkers